<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/RedHill-Biopharma-Ltd-Sponsored-ADR-US7574681034">RedHill Biopharma Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/26/3301289/0/en/Bessor-Announces-Entering-Option-for-the-Redhill-Property.html">Bessor Announces Entering Option for the Redhill Property</a>
    </div>

      <div class="me-0 me-md-5">
        Vancouver, BC, May 26, 2026 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) (&quot;Bessor&quot; or the “Corporation”) announces that, on February 9, 2026, it entered into an agreement (the “Agreement”) with Homegold Resources Ltd. (“Homegold”) and Johan Shearer (“Shearer”), pursuant to which Bessor terminated its option to acquire a 100% interest in the Redhill property, located south of Ashcroft, B....
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/RedHill-Biopharma-Ltd-Sponsored-ADR-US7574681034">RedHill Biopharma Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/redhills-rhb-204-demonstrates-comparable-map-killing-efficacy-to-rhb-104---important-step-in-rhb-204-development-for-map-related-crohns-disease-302758691.html">RedHill&#39;s RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn&#39;s Disease</a>
    </div>

      <div class="me-0 me-md-5">
        RHB-2041 is a next-generation optimized formulation of RedHill&#39;s oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn&#39;s disease (CD) In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical si...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/RedHill-Biopharma-Ltd-Sponsored-ADR-US7574681034">RedHill Biopharma Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/redhill-biopharma-announces-full-year-2025-financial-results-and-operational-highlights-302754141.html">RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights</a>
    </div>

      <div class="me-0 me-md-5">
        2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partnership with Cumberland Pharmaceuticals (&quot;Cumberland&quot;) (Nasdaq: CPIX), including Cumberland&#39;s $4 million investment for a 30% equity interest in THI planned to drive Talicia growth, and potentially add...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/RedHill-Biopharma-Ltd-Sponsored-ADR-US7574681034">RedHill Biopharma Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/redhills-opaganib-enhances-efficacy-of-neuroblastoma-chemo-combination-and-augment-anti-tumor-immunity-in-triple-negative-breast-cancer-in-preclinical-studies--new-data-presented-at-aacr-2026-302750239.html">RedHill&#39;s Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026</a>
    </div>

      <div class="me-0 me-md-5">
        New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC) The positive NB data from studies undertaken by Penn State University&#39;s Jeremy Hengst and Apogee Biotechnology, and funde...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/RedHill-Biopharma-Ltd-Sponsored-ADR-US7574681034/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>